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Serum Selenium in Lymphoma
TO THE EDITOR: We read with interest the paper by Last
et al1 in a recent issue of Journal of Clinical Oncology. The
authors observed that serum selenium concentration at pre-
sentation predicted for dose delivery, response to therapy, and
long-term survival in patients with aggressive non-Hodgkin’s
lymphoma (NHL). They speculate that the underlying mech-
anisms may include prevention of chemoresistance, enhance-
ment of immune function, cytotoxic activity of selenium
compounds, and reduction of chemotherapy side effects. They
also allude to the possibility that low serum selenium could
just be a marker of general nutritional deficiency or an acute
phase reactant. However, the authors failed to consider an-
other important possibility; that is, that selenium concentra-
tion could be a marker of disease proliferation. From our own
data published approximately 15 years ago, we think that this is
the most likely explanation.
In the first study, we measured serum trace elements in
small groups of patients with various hematologic malig-
nancies.2 Although serum selenium was normal in patients
with multiple myeloma, chronic lymphocytic leukemia
(CLL), and myeloproliferative disorders, it was apparently
decreased in those with Hodgkin’s lymphoma or non-
Hodgkin’s lymphoma (not significant). This was later con-
firmed by others.3 We then carried out a more detailed
study in 50 patients with CLL and 100 normal participants.4
Although serum selenium was similar overall in CLL pa-
tients compared with levels in the controls, levels were
significantly lower in Rai stages 3 to 4 compared to Rai
stages 0 to 2 (0.079  0.011 v 0.108  0.006 g/mL; P 
.0390). In addition, serum selenium correlated negatively
(P .05) with the lymphocyte count in patients with more
than 20  109/L lymphocytes. Therefore, serum selenium
seemed to be related to the extent of the disease. However,
we emphasized that we could not determine whether differ-
ences in selenium levels were responsible for or caused by
tumor proliferation. In a final study, serum selenium levels
were measured before, during, and after high-dose induc-
tion chemotherapy in 70 patients with acute myelogenous
leukemia (AML).5 Pretreatment serum selenium levels
were lower in patients than in controls (0.082  0.033 v
0.097  0.035 g/mL; P  .01) and correlated inversely
with the absolute peripheral blast cell count (P .001) and
other measures of the tumor burden. After 7 days of che-
motherapy, selenium increased significantly in proportion
to the initial tumor burden (P  .01). Thereafter, serum
selenium levels remained normal in patients entering a
complete remission, whereas levels gradually decreased to
baseline values in patients who experienced treatment fail-
ure. These data do not lend support to the hypothesis that a
low selenium status enhances the risk of developing AML,
but indicate that serum selenium levels in patients with
AML are mostly dependent on tumor activity.
In view of the close relationship with tumor burden
and the rapid modifications induced by chemotherapy, a
mechanism of selenium sequestration by tumor cells is
possible. Some evidence that certain tumors can accumu-
late selenium has been reported.6 In their article, Last et al
indicate that performance status was the only clinical vari-
able correlating with selenium concentration, but they
do not show any data on such associations with stage, serum
lactate dehydrogenase, International Prognostic Index, tumor
masses, or other factors. In addition, follow-up measurements
during chemotherapy would have been most useful.
Contrary to the conclusions of the authors, we believe
that until all these aspects of selenium metabolism in lym-
phoma patients are clearly sorted out, incorporation of
selenium supplementation into an overall therapeutic strat-
egy is not warranted. It could even have some unforeseen
deleterious effects on outcome.
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